GENE ONLINE|News &
Opinion
Blog

2021-10-19| APAC

WuXi ATU Launches Fourth Manufacturing Site for Gene and Cell Therapy CTDMO Service

by Tyler Chen
Share To

On October 17, WuXi Advanced Therapies (WuXi ATU), a WuXi AppTec subsidiary, launched a new development and manufacturing facility in Lin-gang, Shanghai. This marks WuXi ATU’s fourth production site worldwide.

 

The Fourth Facility for WuXi ATU

Based in the U.S., WuXi ATU provides Contract, Testing, Development and Manufacturing Organization (CTDMO) services for cell and gene therapy. It currently has production sites in the U.S., UK, and China.

Chief Executive Officer of WuXi ATU, Dr. David Chang said, “By expanding our global footprint, we will provide enhanced cell and gene therapy manufacturing services for our customers worldwide and better enable them to deliver more effective and accessible advanced therapies to patients.”

WuXi ATU said the Lin-gang facility has over 200 independent suites and 6 complete production lines, including an independent liquid distribution center and independent GMP standard sterile filling isolator. The plant will collaborate with the other 3 sites to support the global demand for viral vectors and cell therapies.

 

WuXi ATU to Enrich CTDMO Power

As the CTDMO branch of WuXi AppTec, WuXi ATU has powered up its services through collaboration and M&A in the past 2 years. In March 2021, WuXi AppTec acquired OXGENE, UK-based biotech focusing on the discovery and manufacturing of gene and cell products. After the acquisition, OXGENE was placed as a subsidiary of WuXi ATU and became WuXi ATU’s first facility in Europe.

At the end of 2020, WuXi ATU teamed up with German biotech ViGeneron to accelerate the clinical development of ophthalmic gene therapy, VG901. The drug is used to treat patients with Retinitis pigmentosa (RP), a rare genetic disorder with no approved therapy so far.

WuXi ATU also expanded the facilities in its Philadelphia Navy Yard campus to triple the advanced testing capacity in November 2020. The site is expected to provide testing services for cell and gene therapy worldwide.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Gilead Acquires Arcellx for $7.8B to Advance Anito-cel in Multiple Myeloma
2026-02-24
Lilly Acquires Orna Therapeutics in $2.4B to Scale In Vivo CAR-T Cell Therapies
2026-02-10
Clarity, Courage, and Global Scale: How WuXi Global Forum 2026 Is Shaping What Comes Next
2026-01-19
LATEST
ICE Launches Private Credit Intelligence Platform with Apollo Global Management as Anchor Partner
2026-03-17
Local Bounti Secures $15 Million to Enhance Sustainable Farming and Expand Operations
2026-03-17
Alpha and Omega Semiconductor Introduces 25V and 80V MOSFETs for AI Server Power Demands
2026-03-17
Alviere and Oracle Collaborate to Integrate Embedded Finance Platform with Cloud Solutions for Regulated Global Enterprises
2026-03-17
Fifth Third Bank Introduces Digital Tools for Tracking Cash Flow and Spending Patterns
2026-03-17
MIND Technology Establishes New Trade Credit Facility to Support Operations
2026-03-17
Alebund Pharmaceuticals Partners with R1 Therapeutics for AP306 Kidney Disease Treatment in Asian Markets
2026-03-17
Scroll to Top